Ben Staal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ben Staal has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Brian B. Haab
Van Andel Institute, Grand Rapids, MI, USA
2 shared publications - Randall E. Brand
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
2 shared publications - Ying Huang
Biostatistics Bioinformatics and Epidemiology Vaccine and Infectious Diseases Division Fred Hutchinson Cancer Center
2 shared publications - Aatur D. Singhi
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
1 shared publication Anirban Maitra
MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA
1 shared publicationAnna Lokshin
University of Pittsburgh Medical Center, 200 Lothrop St., Pittsburgh, PA, 15213-2582, USA
1 shared publication
Latest Publications
- Open Access
- 7 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (10) , eadt0029
Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples
Pancreatic ductal adenocarcinoma (PDAC) tumor heterogeneity impedes the development of biomarker assays for early disease detection. We hypothesized that PDAC cell subpopulations could be identified by aberrant glycan signatures in both tumor tissue and blood samples. We used multiplexed glycan immunofluorescence to distinguish between PDAC and noncancer cell subpopulations within tumor tissue, and we developed hybrid glycan sandwich assays to determine whether the aberrant glycan signatures could be detected in blood samples. We found that PDAC cells were identified by signatures of glycans detected by four glycan-binding proteins (VVL, CA19-9, sTRA, and GM2) and that there are three types of glycan-defined PDAC tumors: sTRA type, CA19-9 type, and intermixed. In patient-matched tumor and blood samples, the PDAC tumor type could be determined by the aberrant glycans in the blood. As a result, the combined assays of aberrant glycan signatures were more sensitive and specific than any individual assay. Our results demonstrate a methodology to detect and stratify PDAC.
- 7 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (10) , eadt0029
Open AccessMultiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples
Pancreatic ductal adenocarcinoma (PDAC) tumor heterogeneity impedes the development of biomarker assays for early disease detection. We hypothesized that PDAC cell subpopulations could be identified by aberrant glycan signatures in both tumor tissue and blood samples. We used multiplexed glycan immunofluorescence to distinguish between PDAC and noncancer cell subpopulations within tumor tissue, and we developed hybrid glycan sandwich assays to determine whether the aberrant glycan signatures could be detected in blood samples. We found that PDAC cells were identified by signatures of glycans detected by four glycan-binding proteins (VVL, CA19-9, sTRA, and GM2) and that there are three types of glycan-defined PDAC tumors: sTRA type, CA19-9 type, and intermixed. In patient-matched tumor and blood samples, the PDAC tumor type could be determined by the aberrant glycans in the blood. As a result, the combined assays of aberrant glycan signatures were more sensitive and specific than any individual assay. Our results demonstrate a methodology to detect and stratify PDAC.
- Open Access
- 13 September 2024
- Published by Elsevier in Cancer Letters
- Vol. 604, 217245
A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone
- 13 September 2024
- Published by Elsevier in Cancer Letters
- Vol. 604, 217245
Open AccessA rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone